PASG

Investor Moves

Name	Value	Action	Change	Price	Last Price
Ken GriffinCitadel Advisors $-208.4K ExitQ1 2026 $208k -- $4.83
Jim SimonsRenaissance Technologies $1M133.6k shares TrimQ1 2026 $238k $7.85 $4.83
Ken GriffinCitadel Advisors $55.5K AddQ4 2025 $55k -- $4.83
Jim SimonsRenaissance Technologies $477.9K AddQ4 2025 $478k -- $4.83

Insider Trades

Name	Value	Action	Price	Last Price
Chou WilliamDirector, Officer: PRESIDENT AND CEO $75k4.1k shares SellJan 8, 2026 $18.44 $4.83
Borthwick KathleenCFO $38k2.1k shares SellJan 8, 2026 $18.44 $4.83
Lynx1 Capital Management LP10 Percent Owner $2.3k325 shares BuySep 11, 2025 $6.96 $4.83
Lynx1 Capital Management LP10 Percent Owner $138k19.8k shares BuySep 12, 2025 $6.99 $4.83
Lynx1 Capital Management LP10 Percent Owner $83k11.9k shares BuySep 15, 2025 $6.99 $4.83
Lynx1 Capital Management LP10 Percent Owner $379k66.4k shares BuyJul 24, 2025 $5.71 $4.83

News

globenewswire.comPassage Bio Reports Updated Interim Data from upliFT-D Trial and Provides Regulatory and Corporate Updatesglobenewswire.comApr 20

Trade PASG

About Passage Bio, Inc.

Passage Bio, Inc. is a biopharmaceutical company dedicated to pioneering genetic therapies for conditions affecting the central nervous system. Their advanced pipeline includes PBGM01, designed to treat infantile GM1 gangliosidosis by utilizing a proprietary AAVhu68 capsid to deliver a functional GLB1 gene, which codes for the lysosomal acid beta-galactosidase enzyme, to both the brain and peripheral tissues. Another key program, PBFT02, employs an AAV1 capsid to introduce a functional granulin (GRN) gene, encoding progranulin (PGRN), to the brain as a treatment for FTD-GRN. Additionally, PBKR03 is under development for infantile Krabbe disease, leveraging a proprietary AAVhu68 capsid to deliver a functional GALC gene, responsible for producing the hydrolytic enzyme galactosylceramidase, to the brain and surrounding tissues. The company's portfolio also features PBML04 for metachromatic leukodystrophy, PBAL05 for amyotrophic lateral sclerosis, and PBCM06 for Charcot-Marie-Tooth Type 2A. Passage Bio maintains a significant research collaboration with the Trustees of the University of Pennsylvania's Gene Therapy Program, alongside a development services and clinical supply agreement with Catalent Maryland, Inc. Established in 2017, the company's headquarters are located in Philadelphia, Pennsylvania.

CEO: William Chou
IPO Date: Feb 28, 2020

Market Data

Open: $5.46
High: $5.89
Low: $4.92
Volume: 71.9K
52W High: $20.00
52W Low: $3.94

Valuation

Market Cap: $16.5M
Enterprise Value: -$11.1M

Financials

Free Cash Flow: -$31.5M
Revenue: $0
Net Income: -$45.5M
Cash: $46.3M
Debt: $24M

Events

EarningsAug 11

EPS est. -2.438